A new clinical trial shows that combining a chemotherapy drug called S-1 with a precise form of radiation therapy helps older patients with inoperable esophageal cancer live longer. The study included patients aged 70 and older who could not have surgery. They were given either radiation alone or radiation plus S-1 chemotherapy.
After a median follow-up of 75 months, the group receiving both treatments had better overall survival. At five years, 34.1% of patients in the combination group were alive, compared with 23.6% in the radiation-only group. The combination also improved progression-free survival and reduced the chance of the cancer returning in the same area.
The study did not report on side effects or how well patients tolerated the treatment. This information is important for understanding the full picture. The results are promising, but more details on safety are needed before this becomes a standard approach.
For now, this treatment option may be considered for older patients with inoperable esophageal cancer. Anyone considering this therapy should discuss the potential benefits and risks with their doctor.